A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
Phase 1
- Conditions
- Melanoma Stage IVUnresectable MelanomaNSCLC Stage IV
- Interventions
- Biological: Fecal Microbial Transplantation by capsules
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Ella Therapeutics Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT04521075
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
© Copyright 2025. All Rights Reserved by MedPath